Shopping Cart
- Remove All
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
100 μg | $814 | 7-10 days | |
500 μg | $3,250 | 7-10 days | |
1 mg | $5,440 | 7-10 days |
Description | Tumor necrosis factor receptor superfamily, member 4 (TNFRSF4), also known as CD134 and OX40 receptor. OX40 is a secondary co-stimulatory immune checkpoint molecule, expressed after 24 to 72 hours following activation; its ligand, OX40L, is also not expressed on resting antigen presenting cells, but is following their activation. OX40/TNFRSF4 Protein (Primary Amine Labeling), Human, Recombinant (hFc), Biotinylated is expressed in HEK293 mammalian cells with C-hFc tag. The predicted molecular weight is 46.8 kDa and the accession number is P43489. |
Species | Human |
Expression System | HEK293 Cells |
Tag | C-hFc |
Accession Number | P43489 |
Synonyms | IMD16,ACT-135,OX40 homologue,Ly-70, TXGP1L,TNFRSF4,OX40,OX40L receptor,CD134 |
Construction | Leu29-Ala216 |
Protein Purity | > 95% as determined by Tris-Bis PAGE |
Molecular Weight | 46.8 kDa (predicted). Due to glycosylation, the protein migrates to 72-75 kDa based on Tris-Bis PAGE result. |
Endotoxin | < 1 EU/μg by the LAL method. |
Formulation | Supplied as 0.22 μm filtered solution in PBS (pH 7.4). |
Stability & Storage | It is recommended to store the product under sterile conditions at -70°C or lower. Samples are stable for up to 12 months at -80°C. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
Shipping | In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice. |
Research Background | Tumor necrosis factor receptor superfamily, member 4 (TNFRSF4), also known as CD134 and OX40 receptor. OX40 is a secondary co-stimulatory immune checkpoint molecule, expressed after 24 to 72 hours following activation; its ligand, OX40L, is also not expressed on resting antigen presenting cells, but is following their activation. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.